Currently, there are 59.20M common shares owned by the public and among those 57.63M shares have been available to trade.
The company’s stock has a 5-day price change of -3.71% and 27.37% over the past three months. ALDX shares are trading 3.42% year to date (YTD), with the 12-month market performance down to -65.49% lower. It has a 12-month low price of $1.42 and touched a high of $10.78 over the same period. ALDX has an average intraday trading volume of 475.29K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.14%, -8.91%, and -4.01% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares accounts for 60.55% of the company’s 59.20M shares outstanding.
It has a market capitalization of $215.66M and a beta (3y monthly) value of 1.46. The earnings-per-share (ttm) stands at -$0.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.22% over the week and 5.17% over the month.
Analysts forecast that Aldeyra Therapeutics Inc (ALDX) will achieve an EPS of -0.15 for the current quarter, -0.17 for the next quarter and -0.49 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.17 while analysts give the company a high EPS estimate of -0.17. Comparatively, EPS for the current quarter was -0.15 a year ago. Earnings per share for the fiscal year are expected to increase by 63.07%, and -107.21% over the next financial year.
Looking at the support for the ALDX, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on April 03, 2024, with the firm’s price target at $10. H.C. Wainwright coverage for the Aldeyra Therapeutics Inc (ALDX) stock in a research note released on April 02, 2024 offered a Buy rating with a price target of $10. H.C. Wainwright was of a view on April 27, 2022 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on February 08, 2021, issuing a price target of $26. Berenberg on their part issued Buy rating on December 16, 2020.
